STOCKS TELEGRAPH

Tag: Kintara Therapeutics

  • Kintara Therapeutics (KTRA) Sees Market Recovery Post Friday Downturn

    Shares of Kintara Therapeutics, Inc. (Nasdaq: KTRA) experienced a sluggish trading session on Friday, dipping nearly 5%. However, the pre-market session today hints at a slight rebound, showing a 2% increase.

    Key Corporate Updates

    Kintara, a company specializing in cancer therapies, recently unveiled significant developments:

    1. Initiation of REM-001 Study

      Kintara commenced an open-label study evaluating REM-001 in cutaneous metastatic breast cancer patients. This study, funded primarily by a $2.0 million grant from the National Institutes of Health, aims to optimize treatment protocols before moving to a Phase 3 trial.

    2. Strategic Review Underway

      The company’s Board of Directors initiated a strategic review process to enhance shareholder value, enlisting Ladenburg Thalmann & Co. Inc. as its financial advisor.

    3. Focus Shift to REM-001

      Following preliminary results from the GBM AGILE study, which indicated no significant improvement with VAL-083 in glioblastoma treatment, Kintara redirected its focus to REM-001, discontinuing the development of VAL-083.

    Financial Snapshot

    In its fiscal second-quarter results, ending December 31, 2023, Kintara reported:

    • Cash and cash equivalents of approximately $0.7 million as of December 31, 2023.
    • Net proceeds of approximately $6.1 million from the sale of common stock in early 2024.
    • A net loss of approximately $1.0 million for the three months ended December 31, 2023, attributed to lower research and development expenses and reduced general and administrative costs.

    Market Dynamics

    Recent market activity has garnered attention towards Kintara’s stock. Notable spikes in trading volume and positive indicators have piqued investor interest. The successful completion of an ATM facility, along with strengthened shareholder equity and the absence of trading constraints, further augments market sentiment.

    Conclusion

    Kintara Therapeutics navigates a dynamic market environment with strategic maneuvers and promising developments in its product pipeline. Despite encountering recent hurdles, the company’s proactive initiatives and favorable market dynamics position it for potential growth. Investors remain vigilant as Kintara advances its mission to pioneer innovative cancer therapies.

  • What Do You Think Has Boosted KTRA Stock This Morning?

    As of the last check, shares of biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, Kintara Therapeutics Inc. (KTRA) were trading at $2.80, an increase of 23.35%. Kintara stock closed at $2.27 in the previous session. Volume for KTRA stock remained at 4.81 million shares, which is above the past 50 days’ average of 1.15 million shares.

    In the past week, KTRA shares have gained 1.34%, with this year’s performance of 230.04%. During a three-month period, KTRA stock gained 30.46%, and over a six-month period, it gained 71.97%. Additionally, KTRA has a current market capitalization of $74.68 million and still has 29.27 million outstanding shares. Following topline results from a phase 2 clinical trial, KTRA stock has been rising.

    Why did KTRA conduct the trial?

    Kintara, which has its headquarters in San Diego, California, focuses on the development of novel cancer therapies. In addition to VAL-083, KTRA is developing REM-001 for cutaneous metastatic breast cancer (CMBC), both of which are Phase 3-ready. A novel blood-brain barrier crossing, small molecule, bifunctional alkylating agent by KRTA, called VAL-083, has shown clinical activity against a variety of cancers. KTRA’s proprietary, late-stage photodynamic therapy platform, REM-001, demonstrates promise for localized cutaneous tumor treatment and for other potential applications.

    In its open-label, Phase 2 clinical study of its lead compound VAL-083, Kintara today announced topline data results from the recurrent arm.

    • The study was conducted by KTRA at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas.
    • In Phase 2 of KTRA’s study, the treatment will be tested in patients with the unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene in glioblastoma multiforme (GBM) patients.
    • In the recurrent arm of the KTRA study, temozolomide was pre-treated prior to disease recurrence in patients with temozolomide pre-treatment.
    • A total of 89 patients were enrolled at KTRA, who were initially treated with 30 mg/m2/day on days 1, 2, and 3 of a 21-day cycle.
    • The 30 mg dose being examined is the same dose being tested in KTRA’s recently initiated and currently enrolling GBM AGILE study arm, VAL-083.

    An overview of the results:

    • The median overall survival (mOS) of the 48 efficacy-evaluable patients initially treated with 30 mg / m2 / day was found to be 8.0 months in the KTRA study.
    • Similary to KTRA’s prior research, the most frequent adverse event was myelosuppression.
    • Among patients receiving VAL-083 at 30 mg/m2/day, five experienced a serious adverse event (SAE) possibly related to the drug.
    • KTRA observed that mOS was 7.5 months for 83 efficacy evaluable patients who had completed at least one cycle of treatment.

    The FDA and European Medicines Agency have granted KTRA’s VAL-083 an Orphan Drug Designation for GBM. The FDA has also authorized Kintara (KTRA) to use it for the treatment of medulloblastoma and ovarian cancer, granting it Orphan Drug Designation for the same. Furthermore, KTRA’s VAL-083 in recurrent GBM has been given Fast Track Designation by the FDA.